A new study from an international team led by the U.S. Dept. of Energy (DOE)’s Oak Ridge National Laboratory (ORNL) is guiding drug designers toward improved pharmaceuticals to treat HIV. The scientists used neutrons and x-rays to study the interactions between HIV protease, a protein produced by the HIV virus, and an antiviral drug commonly used to block virus replication.
Using neutrons from the Institut Laue-Langevin in Grenoble, France, the researchers gained a never-before-seen view of hydrogen bonds that connect the HIV protease and the drug. Unlike x-rays, neutrons can easily detect the position of hydrogen atoms.
“Knowing where hydrogen atoms are located gives researchers a much better idea about the nature and strength of the interactions,” said lead author Andrey Kovalevsky of ORNL. “By applying neutron crystallography we have effectively increased the clarity of this picture, because hydrogen atoms become visible in the neutron structures. Using neutrons, we are now able to see every atom in a protein-drug complex, all the way to the smallest atom in nature.”
The research, published in the Journal of Medicinal Chemistry, presents drug designers with a set of new potential sites for the improvement of the drug’s surface chemistry to significantly strengthen the binding, thereby increasing the effectiveness of the drugs and reducing the necessary dosages.
Several new instruments suited to the study of proteins are scheduled come online over the next year at ORNL’s two neutron facilities—the Spallation Neutron Source and the High Flux Isotope Reactor. Kovalevsky, an instrument scientist for one of the new ORNL instruments, anticipates that the additional capacity for studying protein crystals with neutrons will enable more advances in biomedical research like the HIV protease study.
“We are confident that by combining the two crystallographic techniques—x-rays and neutrons—it will be possible to significantly improve the method of structure-guided drug design,” he said. “This research could ultimately provide patients with newer more effective medicines to not only battle HIV infection, but for other diseases as well.”
Source: Oak Ridge National Laboratory